Misplaced Pages

#834165

42-441: CR3 or CR-3 may refer to: Science and technology [ edit ] Macrophage-1 antigen , an immunological cell surface receptor for a complement component CR3, an x86 microprocessor control register CR3, a raw image format used by Canon digital cameras since 2018 Transportation [ edit ] Cessna CR-3 , a racing aircraft designed in 1933 Curtiss CR-3 ,

84-435: A T Cell Receptor (a TCR) and an HLA-peptide complex. As a result of that conjunction a signalling pathway (signalling a cell's protein making machinery to express or 'make' IL-2), a PhosphoLipase-C (PLC) dependent pathway, is set up. PLC activates 3 major transcription factors and their pathways: NFAT , NFkB and AP-1 . In addition and after costimulation from CD28 the optimal activation of expression of IL-2 and these pathways

126-407: A broad range of doses, without serious side effects. Tumour blood vessels are more vulnerable than normal blood vessels to the actions of IL-2. When injected inside a tumor, i.e. local application, a process mechanistically similar to the vascular leakage syndrome, occurs in tumor tissue only. Disruption of the blood flow inside of the tumor effectively destroys tumor tissue. In local application,

168-549: A free cytokine, mammalian IL-2 that is secreted by activated T cells is important for a negative feedback loop by the stimulation of regulatory T cells, the latter being the cells with the highest constitutive IL-2Rα (aka CD25) expression. Besides this negative feedback loop, mammalian IL-2 also participates in a positive feedback loop because activated T cells enhance their own IL-2Rα expression. As in mammals, fish IL-2 also stimulates T cell proliferation and appears to preferentially stimulate regulatory T cells. Fish IL-2 induces

210-456: A manner reminiscent of how mammalian IL-15 binds to IL-15Rα. Despite fish IL-2 and IL-15 sharing the same IL-15Rα chain, the stability of fish IL-2 is independent of it whereas IL-15 and especially IL-15L depend on binding to (co-presentation with) IL-15Rα for their stability and function. This suggests that, like in mammals, fish IL-2, in contrast to fish IL-15 and IL-15L, is not relying on "in trans" presentation by its receptor alpha chain. As

252-406: A point of disagreement. The commercial interest in local IL-2 therapy has been very low. Because only a very low dose IL-2 is used, treatment of a patient would cost about $ 500 commercial value of the patented IL-2. The commercial return on investment is too low to stimulate additional clinical studies for the registration of intratumoral IL-2 therapy. Usually, in the U.S., the higher dosage option

294-400: A promising immunotherapeutic agent due to significant drawbacks which are listed above. Some of the issues can be overcome using IL-2 ic. They are composed of IL-2 and some of its monoclonal antibody (mAb) and can potentiate biologic activity of IL-2 in vivo . The main mechanism of this phenomenon in vivo is due to the prolongation of the cytokine half-life in circulation. Depending on

336-463: A racing aircraft designed in 1921 County Road 3 (disambiguation) , several roads Loyang MRT station , Singapore, station code CR3 Other uses [ edit ] The royal cypher C III R (sometimes written as CR III ) for Charles III Rex ( Charles III , King) Crystal River 3 Nuclear Power Plant CR3, a postcode district in the CR postcode area [REDACTED] Topics referred to by

378-843: A response of CR3 and CR4 to enable complement-dependent cell cytotoxicity towards antibody-coated cancer cells. Such biological therapeutic targeting is characterized by lowering autoimmune inflammation or enhancing anti-cancer vaccination effects. Leukadherin-1, a CR3 agonist molecule, has been shown to suppress human innate inflammatory signals. Its anti-inflammatory effect mediation further provides support for its therapeutic promise in animal models of vascular injury. Interleukin 2 1IRL , 1M47 , 1M48 , 1M49 , 1M4A , 1M4B , 1M4C , 1NBP , 1PW6 , 1PY2 , 1QVN , 1Z92 , 2B5I , 2ERJ , 3QAZ , 3QB1 , 3INK , 4NEJ , 4NEM 3558 16183 ENSG00000109471 ENSMUSG00000027720 P60568 P04351 NM_000586 NM_008366 NP_000577 NP_032392 Interleukin-2 ( IL-2 )

420-416: A similar genomic location. In fish, IL-2 shares a single receptor alpha chain with its related cytokines IL-15 and IL-15-like (IL-15L). This "IL-15Rα" receptor chain is similar to mammalian IL-15Rα, and in tetrapod evolution a duplication of its coding gene plus further diversification created mammalian IL-2Rα. Sequences, and structural analysis of grass carp IL-2, suggest that fish IL-2 binds IL-15Rα in

462-522: A variety of cells and circumstances. Upregulation of Mac-1 in the presence of certain factors such as IL-2 may cause a prolongation of the life of the immune cell while the presence of TNF-α induces apoptosis and selective removal of the cell. A fully activated neutrophil may express on its membrane 200,000 or more CR3 molecules. Absence of CR3 results in reduced binding and ingestion of Mycobacterium tuberculosis in mice. In human mononuclear phagocytes, phagocytosis of Mycobacterium tuberculosis

SECTION 10

#1732797660835

504-683: Is a pattern recognition receptor , capable of recognizing and binding to many molecules found on the surfaces of invading bacteria. CR3 also recognizes iC3b when bound to the surface of foreign cells. iC3b is generated by proteolysis of C3b and binding to the receptor causes phagocytosis and destruction of the foreign cell opsonized with iC3b. CR3 belongs to a family of cell surface receptors known as integrins (because they share this particular β chain, they are referred to as β2-integrins), which are extremely widely distributed throughout nature and which generally are important in cellular adhesion, migration, phagocytosis and other cell-cell interactions in

546-464: Is a recombinant IL-2 with a serine at residue 125, sold by Shenzhen Neptunus. Neoleukin 2/15 is a computationally designed mimic of IL-2 that was designed to avoid common side effects. However, clinical trials into this candidate were discontinued. Various dosages of IL-2 across the United States and across the world are used. The efficacy and side effects of different dosages is often

588-579: Is an interleukin , a type of cytokine signaling molecule in the immune system . It is a 15.5–16  kDa protein that regulates the activities of white blood cells (leukocytes, often lymphocytes ) that are responsible for immunity. IL-2 is part of the body's natural response to microbial infection , and in discriminating between foreign ("non-self") and "self". IL-2 mediates its effects by binding to IL-2 receptors , which are expressed by lymphocytes. The major sources of IL-2 are activated CD4 T cells and activated CD8 T cells . Put shortly

630-477: Is commenced by IL-2 binding to its receptor, following which cytoplasmatic domains of CD122 and CD132 heterodimerize . This leads to the activation of Janus kinases JAK1 and JAK3 which subsequently phosphorylate T338 on CD122. This phosphorylation recruits STAT transcription factors , predominantly STAT5 , which dimerize and migrate to the cell nucleus where they bind to DNA . with an "express other proteins" signal. The proteins expressed by means of

672-543: Is dephosphorylated and therefore translocated to the nucleus. AP-1 is a dimer and is composed of c-Jun and c-Fos proteins. It cooperates with other transcription factors including NFkB and Oct. NFkB is translocated to the nucleus after costimulation through CD28. NFkB is a heterodimer and there are two binding sites on the IL-2 promoter. IL-2 has essential roles in key functions of the immune system, tolerance and immunity , primarily via its direct effects on T cells . In

714-463: Is different from Wikidata All article disambiguation pages All disambiguation pages Macrophage-1 antigen The integrin α chain is noncovalently bound to the integrin β chain. It binds to iC3b and can be involved in cellular adhesion, binding to the intercellular adhesion molecule-1 ( ICAM-1 ). CR3 causes phagocytosis and destruction of cells opsonized with iC3b. CR3 and CR4 are thought to exhibit overlapping functions; however,

756-577: Is expressed by memory CD8 T cells and NK cells , whereas regulatory T cells and activated T cells express high levels of trimeric IL-2R. Instructions to express proteins in response to an IL-2 signal (called IL-2 transduction) can take place via 3 different signaling pathways ; they are: (1) the JAK-STAT pathway, (2) the PI3K/Akt/mTOR pathway and (3) the MAPK/ERK pathway. The signalling

798-419: Is generally well tolerated. This is also the case for intralesional IL-2 in other forms of cancer, like nasopharyngeal carcinoma. Eisai markets a drug called denileukin diftitox (trade name Ontak), which is a recombinant fusion protein of the human IL-2 ligand and the diphtheria toxin . This drug binds to IL-2 receptors and introduces the diphtheria toxin into cells that express those receptors, killing

840-615: Is induced. In summary therefore before a cell will make IL-2 in accordance with this pathway there have to be two reactions: TCR+HLA and protein complex on the one hand and CD28 costimulation on the other indeed mere IL-2 ligation to its receptor is too low affinity to enable pathway. At the same time Oct-1 is expressed. It helps the activation. Oct1 is expressed in T-lymphocytes and Oct2 is induced after cell activation. NFAT has multiple family members, all of them are located in cytoplasm and signaling goes through calcineurin, NFAT

882-556: Is involved in itchy psoriasis . Aldesleukin is a form of recombinant interleukin-2. It is manufactured using recombinant DNA technology and is marketed as a protein therapeutic and branded as Proleukin. It has been approved by the Food and Drug Administration (FDA) with a black box warning and in several European countries for the treatment of cancers ( malignant melanoma , renal cell cancer ) in large intermittent doses and has been extensively used in continuous doses. Interking

SECTION 20

#1732797660835

924-609: Is mediated in part by human monocyte complement receptors including CR3. CR3 has also been shown to mediate phagocytosis of the Lyme disease causing bacterium, Borrelia burgdorferi , in the absence of iC3b opsonization. CR3 (integrin α M β 2 ) and CR4 (integrin α X β 2 , composed of CD11c and CD18), both members of the β2-integrin family, are generally thought to exhibit overlapping functions in myeloid cells and certain lymphoid populations. CR3 and CR4 have been shown to be 87% homologous via sequence analysis of human cDNA of

966-461: Is particularly important historically, as it is the first type I cytokine that was cloned, the first type I cytokine for which a receptor component was cloned, and was the first short-chain type I cytokine whose receptor structure was solved. Many general principles have been derived from studies of this cytokine including its being the first cytokine demonstrated to act in a growth factor–like fashion through specific high-affinity receptors, analogous to

1008-647: Is shared by all family members. The IL-2 receptor (IL-2R) α subunit binds IL-2 with low affinity (K d ~ 10 M). Interaction of IL-2 and CD25 alone does not lead to signal transduction due to its short intracellular chain but has the ability (when bound to the β and γ subunit) to increase the IL-2R affinity 100-fold. Heterodimerization of the β and γ subunits of IL-2R is essential for signalling in T cells . IL-2 can signalize either via intermediate-affinity dimeric CD122/CD132 IL-2R (K d ~ 10 M) or high-affinity trimeric CD25/CD122/CD132 IL-2R (K d ~ 10 M). Dimeric IL-2R

1050-449: Is tightly regulated and functions as part of both transient positive and negative feedback loops in mounting and dampening immune responses. Through its role in the development of T cell immunologic memory, which depends upon the expansion of the number and function of antigen-selected T cell clones, it plays a key role in enduring cell-mediated immunity . IL-2 has been discovered in all classes of jawed vertebrates, including sharks, at

1092-421: Is used, affected by cancer type, response to treatment and general patient health. Patients are typically treated for five consecutive days, three times a day, for fifteen minutes. The following approximately 10 days help the patient to recover between treatments. IL-2 is delivered intravenously on an inpatient basis to enable proper monitoring of side effects. A lower dose regimen involves injection of IL-2 under

1134-584: Is vascular leak syndrome (VLS; also termed capillary leak syndrome ). It is caused by lung endothelial cells expressing high-affinity IL-2R. These cells, as a result of IL-2 binding, causes increased vascular permeability. Thus, intravascular fluid extravasate into organs, predominantly lungs, which leads to life-threatening pulmonary or brain oedema. Other drawbacks of IL-2 cancer immunotherapy are its short half-life in circulation and its ability to predominantly expand regulatory T cells at high doses. Intralesional IL-2 used to treat in-transit melanoma metastases

1176-418: The thymus , where T cells mature, it prevents autoimmune diseases by promoting the differentiation of certain immature T cells into regulatory T cells , which suppress other T cells that are otherwise primed to attack normal healthy cells in the body. IL-2 enhances activation-induced cell death (AICD) . IL-2 also promotes the differentiation of T cells into effector T cells and into memory T cells when

1218-458: The T and B lymphocytes and NK cells. For instance, while both CR3 and CR4 are involved in adhesion, migration and proliferation of B cells, they are involved in enhancing complement-dependent cytotoxicity in NK cells. Immunomodulatory therapies often aim for an induced reduction of symptoms in inflammatory disease or supported elimination of malignancies. In vitro and in vivo experiments suggest

1260-810: The cells. In some leukemias and lymphomas, malignant cells express the IL-2 receptor, so denileukin diftitox can kill them. In 1999 Ontak was approved by the U.S. Food and Drug Administration (FDA) for treatment of cutaneous T cell lymphoma (CTCL). IL-2 does not follow the classical dose-response curve of chemotherapeutics. The immunological activity of high and low dose IL-2 show sharp contrast. This might be related to different distribution of IL-2 receptors (CD25, CD122, CD132) on different cell populations, resulting in different cells that are activated by high and low dose IL-2. In general high doses are immune suppressive, while low doses can stimulate type 1 immunity. Low-dose IL-2 has been reported to reduce hepatitis C and B infection. IL-2 has been used in clinical trials for

1302-530: The clone of IL-2 mAb, IL-2 ic can selectively stimulate either CD25 (IL-2/JES6-1 complexes), or CD122 cells (IL-2/S4B6). IL-2/S4B6 immune complexes have high stimulatory activity for NK cells and memory CD8 T cells and they could thus replace the conventional IL-2 in cancer immunotherapy . On the other hand, IL-2/JES6-1 highly selectively stimulate regulatory T cells and they could be potentially useful for transplantations and in treatment of autoimmune diseases . According to an immunology textbook: "IL-2

CR3 - Misplaced Pages Continue

1344-405: The distinct binding sites to iC3b suggests differences in their functions. Additionally, CR3 has been shown to have therapeutic promise. Macrophage-1 antigen (hereafter complement receptor 3 or CR3 ) (CD11b/CD18) is a human cell surface receptor found on B and T lymphocytes , polymorphonuclear leukocytes (mostly neutrophils), NK cells , and mononuclear phagocytes like macrophages . CR3

1386-517: The expression of cytokines of both type 1 (Th1) and type 2 (Th2) immunity. As has been found in some studies on mammalian IL-2, data suggest that fish IL-2 can form homodimers and that this is an ancient property of the IL-2/15/15L-family cytokines. Homologues of IL-2 have not been reported for jawless fish (hagfish and lamprey) or invertebrates. While the causes of itchiness are poorly understood, some evidence indicates that IL-2

1428-464: The function of IL-2 is to stimulate the growth of helper, cytotoxic and regulatory T cells. IL-2 is a member of a cytokine family, each member of which has a four alpha helix bundle ; the family also includes IL-4 , IL-7 , IL-9 , IL-15 and IL-21 . IL-2 signals through the IL-2 receptor , a complex consisting of three chains, termed alpha ( CD25 ), beta ( CD122 ) and gamma ( CD132 ). The gamma chain

1470-448: The initial T cell is also stimulated by an antigen , thus helping the body fight off infections. Together with other polarizing cytokines, IL-2 stimulates naive CD4 T cell differentiation into T h 1 and T h 2 lymphocytes while it impedes differentiation into T h 17 and folicular T h lymphocytes. IL-2 increases the cell killing activity of both natural killer cells and cytotoxic T cells . Its expression and secretion

1512-487: The level of dosing usually determines the severity of the side effects. In the case of local IL-2 application, the therapeutic window spans several orders of magnitude. Some common side effects: More serious and dangerous side effects sometimes are seen, such as breathing problems, serious infections , seizures , allergic reactions , heart problems, kidney failure or a variety of other possible complications. The most common adverse effect of high-dose IL-2 therapy

1554-448: The same term This disambiguation page lists articles associated with the same title formed as a letter–number combination. If an internal link led you here, you may wish to change the link to point directly to the intended article. Retrieved from " https://en.wikipedia.org/w/index.php?title=CR3&oldid=1112560169 " Category : Letter–number combination disambiguation pages Hidden categories: Short description

1596-477: The skin typically on an outpatient basis. It may alternatively be given on an inpatient basis over 1–3 days, similar to and often including the delivery of chemotherapy . Intralesional IL-2 is commonly used to treat in-transit melanoma metastases and has a high complete response rate. In preclinical and early clinical studies, local application of IL-2 in the tumor has been shown to be clinically more effective in anticancer therapy than systemic IL-2 therapy, over

1638-433: The systemic dose of IL-2 is too low to cause side effects, since the total dose is about 100 to 1000 fold lower. Clinical studies showed painful injections at the site of radiation as the most important side effect, reported by patients. In the case of irradiation of nasopharyngeal carcinoma the five-year disease-free survival increased from 8% to 63% by local IL-2 therapy Systemic IL-2 has a narrow therapeutic window , and

1680-401: The three pathways include bcl-6 (the PI3K/Akt/mTOR pathway), CD25 & prdm-1 (the JAK-STAT pathway) and certain cyclins (the MAPK/ERK pathway). Gene expression regulation for IL-2 can be on multiple levels or by different ways. One of the checkpoints (in other words one of the things which needs to be done before IL-2 is expressed) is that there must be signaling through a conjunction of

1722-629: The treatment of chronic viral infections and as a booster (adjuvant) for vaccines. The use of large doses of IL-2 given every 6–8 weeks in HIV therapy, similar to its use in cancer therapy, was found to be ineffective in preventing progression to an AIDS diagnosis in two large clinical trials published in 2009. More recently low dose IL-2 has shown early success in modulating the immune system in disease like type 1 diabetes and vasculitis. There are also promising studies looking to use low dose IL-2 in ischaemic heart disease. IL-2 cannot accomplish its role as

CR3 - Misplaced Pages Continue

1764-436: The α chains; however, the complement receptors bind at distinct sites of iC3b and the intracellular domains differ in length and amino acid sequence, suggesting further differences in their functions. Further, CR3 favors binding to positively charged species, while CR4 binds negatively charged species. It has been shown that both CR3 and CR4 are found in mice and humans. Together, CR3 and CR4 are involved in various functions of

#834165